Advisors Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Advisors Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-7,376	Closed	-$577K	–	1579
2020 Q2	$577K	Sell	7,376 -5,443	-42%	-$360K	0.01%	864
2020 Q1	$570K	Sell	12,819 -668	-5%	-$34.7K	0.01%	785
2019 Q4	$576K	Sell	13,487 -399	-3%	-$16.5K	0.01%	941
2019 Q3	$594K	Sell	13,886 -810	-6%	-$44K	0.01%	926
2019 Q2	$933K	Sell	14,696 -455	-3%	-$29K	0.02%	806
2019 Q1	$1.05M	Sell	15,151 -282	-2%	-$16.1K	0.02%	768
2018 Q4	$671K	Buy	15,433 +3,920	+34%	+$214K	0.01%	900
2018 Q3	$879K	Buy	11,513 +9,158	+389%	+$745K	0.01%	882
2018 Q2	$181K	Buy	+2,355	New	+$152K	﹤0.01%	1275

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Advisors Asset Management's RARE Position: Q3 2020 in Review

Advisors Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2020, closing a stake of 7,376 shares — an estimated $577K sold.

Advisors Asset Management first reported a position in RARE in Q2 2018 and held it in 9 quarters. The position peaked at $1.05M in Q1 2019. 207 funds tracked by Wall St. Rank hold RARE as of Q3 2020.

Advisors Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2020 after selling out during the quarter.
Advisors Asset Management sold 7,376 Ultragenyx Pharmaceutical shares in Q3 2020, an estimated $577K.
Advisors Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 9 quarters.
Advisors Asset Management's Ultragenyx Pharmaceutical position peaked at $1.05M in Q1 2019.
207 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2020.

Based on Advisors Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.